Shandong Xinhua Pharmaceutical (Xinhua Pharmaceutical, 00719) has released its 2025 Environmental, Social and Governance Report covering the period from 1 January to 31 December 2025. The document outlines the drug-maker’s climate roadmap, governance upgrades and key operating metrics.
Governance and Ratings • A three-tier ESG structure—Board, Strategic Development Committee and ESG Working Group—has been formalised, while all four board committees are now chaired by independent directors. • External assessments recorded Wind ESG “A”, Sino-Securities ESG “A” and Lvfa ESG “AApi”.
Climate and Environmental Targets • Carbon-peak for energy activities is scheduled “by 2030” with a 30 % cut in CO₂ per RMB10,000 output versus 2020; carbon neutrality is targeted for 2060. • 2025 greenhouse-gas emissions totalled 909,643.88 tCO₂e (Scope 1: 325.25 tCO₂e; Scope 2: 282,108.58 tCO₂e; Scope 3: 627,210.05 tCO₂e). • Environmental spending reached RMB 88.90 million, including RMB 7.06 million for energy-saving retrofits. • Clean-energy consumption stood at 5,946.85 tce, or 7.65 % of total energy use.
Operational Safety and Workforce • Work-safety investment amounted to RMB 12.58 million; 832 drills were conducted with 96.50 % employee participation and zero fatalities reported. • The company employed 7,240 staff (female ratio 43.62 %); average training hours were 26.3 per employee. • All workers exposed to occupational hazards received health examinations, and no occupational-disease cases were recorded.
Innovation and Product Pipeline • R&D expenditure hit RMB 379.73 million; 48 patents were granted and 47 drug approvals obtained. • The pipeline advanced key projects, including small-molecule candidate OAB-14 (phase II) and cardiovascular drug LXH-1211 (phase I). • A “Grand R&D Strategy” continues to drive the shift from generics to innovative and biological drugs.
Supply Chain and Product Quality • Xinhua engaged 737 suppliers; 244 underwent ESG impact assessments, while 89 % signed the Supplier Code of Conduct. • Customer satisfaction averaged 99.68/100; no product recalls or data-security incidents were reported. • Quality management involved 74 training sessions and maintained 100 % compliance in internal and regulatory sampling.
Community and Rural Support • The company ran 20-plus volunteer initiatives, organised blood-donation drives and contributed RMB 225,500 through its “Compassionate One-Day Donation” programme. • Consumption-based aid purchases in Chongqing’s Shizhu County exceeded RMB 160,000, and on-site cadre support drove multiple agribusiness projects.
Management reiterated that ESG goals are now embedded in corporate strategy, with future disclosures to track progress on emission-cutting milestones, supply-chain sustainability and drug-innovation deliverables.